Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain

References

• Global Initiative for Chronic Obstructive Lung Disease. Report; 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed June 1, 2022.
   Google Scholar
• NHS. Chronic obstructive pulmonary disease (COPD). Available from: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/treatment/. Accessed June 1, 2022.
   Google Scholar
• World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed July 1, 2022.
   Google Scholar
• Soriano JB, Kendrick PJ, Paulson KRet al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• National Center for Epidemiology. Carlos III Institute of Health. Availabre from: http://raziel.cne.isciii.es/. Accessed November 1, 2021.
   Google Scholar
• Gómez Sáenz JT, Quintano Jiménez JA, Hidalgo Requena A, et al. Enfermedad pulmonar obstructiva crónica: morbimortalidad e impacto sanitario [Chronic obstructive pulmonary disease: morbimortality and healthcare burden]. Semergen. 2014;40(4):198–204. Spanish.
   PubMedGoogle Scholar
• Izquierdo JL. The burden of COPD in Spain: results from the confronting COPD survey. Respir Med. 2003;97(Suppl C):S61–S69. doi:10.1016/S0954-6111(03)80026-4
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable [Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD]. Arch Bronconeumol. 2021;58:69–81.
   PubMed Web of Science ®Google Scholar
• Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgrad Med. 2020;132(2):198–205. doi:10.1080/00325481.2019.1702834
   PubMed Web of Science ®Google Scholar
• The GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION of COPD (updated 2021), the pocket guide (updated 2021) and the complete list of references examined by the committee. Available from: https://goldcopd.org/. Accessed June 1, 2022.
   Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Study to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (ETHOS). Available from: https://clinicaltrials.gov/ct2/show/NCT02465567. Accessed November 1, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Report; 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed June 1, 2022.
   Google Scholar
• Data on file.
   Google Scholar
• Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137–148. doi:10.2147/COPD.S5237
   PubMedGoogle Scholar
• Spanish National Statistics Institute. Life tables;2020. Available from: https://www.ine.es/. Accessed November 1, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Roflumilast for treating chronic obstructive pulmonary disease 2017. Available from: https://www.nice.org.uk/guidance/ta461. Accessed November 1, 2021.
   Google Scholar
• National COPD Audit Programme. COPD: who cares when it matters most? – outcomes report; 2014. Available from: https://www.rcplondon.ac.uk/projects/outputs/copd-who-cares-when-it-matters-most-outcomes-report-2014. Accessed June 1, 2022.
   Google Scholar
• Samyshkin Y, Kotchie RW, Mörk A-C, Briggs AH, Bateman ED. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15(1):69–82.
   PubMed Web of Science ®Google Scholar
• Botplus. Online database of drug prices in Spain. Available from: https://botplusweb.portalfarma.com/botplus.aspx. Accessed November 1, 2021.
   Google Scholar
• Deductions for medications in Spain. Available from: https://www.sanidad.gob.es/profesionales/farmacia/notasInfor.htm. Accessed November 1, 2021.
   Google Scholar
• Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.
   PubMed Web of Science ®Google Scholar
• AEMPS. CIMA. Available from: https://cima.aemps.es/cima/publico/home.html. Accessed November 1, 2021.
   Google Scholar
• Gisbert R, Brosa M Spanish health costs and cost-effectiveness ratios database: eSalud. Barcelona: Oblikue Consulting, S.L.; 2007. Available from: http://www.oblikue.com/bddcostes/. Accessed November 1, 2021.
   Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? [What is an efficient health intervention in Spain in 2020?] Gaceta Sanitaria. 2020;34(2):189–193 .
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–520. doi:10.1007/s10198-010-0244-4
   PubMed Web of Science ®Google Scholar
• Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and Determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–69.
   PubMed Web of Science ®Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7:00480–2020. doi:10.1183/23120541.00480-2020
   PubMedGoogle Scholar
• Martin A, Shah D, Ndirangu K, et al. Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Res. 2022;8(1):00333–2021.
   PubMedGoogle Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632. doi:10.2147/COPD.S240556
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press; 2006.
   Google Scholar